急性髓性白血病中的免疫抑制细胞:机制和治疗点
Mengnan Liu1, Mengting Yang2,3, Yue Qi2,3
1Department of Cardiovascular Medicine, Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, China.
Frontiers in immunology
|August 7, 2025
概括
免疫疗法在急性髓性白血病 (AML) 中面临挑战,原因是免疫抑制性瘤微环境. 本综述探讨了Tregs,MDSCs,LAMs和Bregs等调节细胞如何阻碍抗白血病免疫力,并讨论了克服这些障碍的策略.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
背景情况:
- 免疫疗法对于急性髓性白血病 (AML) 治疗至关重要.
- 抗白血病微环境具有高度的免疫抑制作用,损害了抗白血病免疫反应.
- 专门的免疫抑制细胞为白血病细胞创造了一个庇护所.
研究的目的:
- 检查免疫抑制细胞在AML病变发生中的作用.
- 分析这些细胞的招募动态和分子机制.
- 审查针对这些免疫抑制调节者的治疗策略.
主要方法:
- 关于AML中免疫抑制细胞的当前研究的文献综述.
- 对驱动免疫抑制的分子机制的分析.
- 对现有和新型免疫治疗方法的评估.
主要成果:
- 调控性T细胞 (Tregs),髓质衍生抑制细胞 (MDSCs),白血病相关巨细胞 (LAMs) 和调控性B细胞 (Bregs) 是AML免疫抑制的关键参与者.
- 这些细胞被招募到白血病利基,并采用特定的机制来抑制免疫功能.
- 准这些细胞为增强AML免疫疗法提供了潜力.
结论:
- 了解免疫抑制细胞的复杂相互作用对于AML治疗至关重要.
- 开发中和这些细胞的策略可以提高免疫治疗的疗效.
- 本综述为未来的AML免疫疗法开发提供了一个框架.
相关概念视频
Cytotoxic T Cells-mediated Immune Response
2.0K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
2.0K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Regulation of Hematopoietic Stem Cells
3.3K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.3K
Cell-mediated Immune Responses
72.7K
Overview
72.7K
Transducer Mechanism: Enzyme-Linked Receptors
2.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.8K
Disorders of Leukocytes
1.1K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
1.1K


